A sensitive cell-based assay for the detection of residual infectious West Nile virus

Vaccine

Volumn 25, Issue 39-40, 2007, Pages 6872-6881

  Koldijk, M H ^a   Bogaards, J A ^a   Kostense, S ^a   de Vocht, M ^a   Gijsbers, L ^a   ter Haak, M ^a   Ophorst, C ^a   Brakenhoff, J P J ^a   Weverling, G J ^a   Guichoux, J Y ^a   UytdeHaag, F ^a   Lewis, J ^b   Goudsmit, J ^a   Marzio, G ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b AecselaBiologics   (United States)

Author keywords

Assay; Inactivation; Virus

Indexed keywords

WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; POISSON DISTRIBUTION; PRIORITY JOURNAL; SAMPLING; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VALIDATION PROCESS; VIRUS DETECTION; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANIMALS, SUCKLING; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C3H; PROPIOLACTONE; VACCINES, INACTIVATED; VERO CELLS; VIRUS INACTIVATION; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 34548569040     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.011     Document Type: Article

References (36)

1. Salk J.E., Bazeley P.L., Bennett B.L., Krech U., Lewis L.J., Ward E.N., et al. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am J Public Health 44 8 (1954) 994-1009
2. Plotkin S.L., and Plotkin S.A. A short story of vacination. In: Plotkin S., and Orenstein W.A. (Eds). Vaccination (1999)
3. Nathanson N., and Langmuir A.D. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background. Am J Hyg 78 (1963) 16-28
4. Para M. An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortaleza, Brazil, in 1960. Residual fixed virus as the etiological agent. Bull World Health Organ 33 2 (1965) 177-182
5. Shapiro S.Z. The HIV/AIDS vaccine researchers' orientation to the process of preparing a US FDA application for an investigational new drug (IND): what it is all about and how you start by preparing for your pre-IND meeting. Vaccine 20 9/10 (2002) 1261-1280
6. Burstyn D.G., and Hageman T.C. Strategies for viral removal and inactivation. Dev Biol Stand 88 (1996) 73-79
7. Aarthi D., Ananda Rao K., Robinson R., and Srinivasan V.A. Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals 32 3 (2004) 153-156
8. Nowak T., Gregersen J.P., Klockmann U., Cummins L.B., and Hilfenhaus J. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol 36 3 (1992) 209-216
9. Putnak R., Barvir D.A., Burrous J.M., Dubois D.R., D'Andrea V.M., Hoke C.H., et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174 6 (1996) 1176-1184
10. Nowak T., Klockman U., and Hilfenhaus J. Inactivation of viruses related to hepatitis C virus by pasteurization in human plasma derivatives. Biologicals 20 1 (1992) 83-85
11. Barrett P.N., Meyer H., Wachtel I., Eibl J., and Dorner F. Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay. J Med Virol 49 1 (1996) 1-6
12. Remington K.M., Trejo S.R., Buczynski G., Li H., Osheroff W.P., Brown J.P., et al. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 87 1 (2004) 10-18
13. Mondal S.K., Neelima M., Seetha Rama Reddy K., Ananda Rao K., and Srinivasan V.A. Validation of the inactivant binary ethylenimine for inactivating rabies virus for veterinary rabies vaccine production. Biologicals 33 3 (2005) 185-189
14. Makoschey B., van Gelder P.T., Keijsers V., and Goovaerts D. Bovine viral diarrhoea virus antigen in foetal calf serum batches and consequences of such contamination for vaccine production. Biologicals 31 3 (2003) 203-208
15. Dichtelmuller H., Rudnick D., Breuer B., and Ganshirt K.H. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone. Biologicals 21 3 (1993) 259-268
16. Appaiahgari M.B., and Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22 2728 (2004) 3669-3675
17. World Health Organisation. Requirements for Japanese enchephalitis vaccine (inactivated) for human use. Requirements for biological substances No. 43. WHO expert committee on biological standardization, Technical report series 771, Annex 6; 1988.
18. World Health Organisation. Requirements for tick-born enchephalitis (inactivated). Requirements for biological substances No. 51. WHO expert committee on biological standardization. Technical report series 889. Annex 2; 1999.
19. European Pharmacopoeia. Tick-borne enchephalitis vaccine (inactivated). Vaccines for human use. 01/2005:1375; 2005.
20. Hayes E.B., and Gubler D.J. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57 (2006) 181-194
21. Steele K.E., Linn M.J., Schoepp R.J., Komar N., Geisbert T.W., Manduca R.M., et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 37 3 (2000) 208-224
22. Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J., Hehir K.M., Keegan J., et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9 13 (1998) 1909-1917
23. Miller R.G. Nonparametric estimators of the mean tolerance in bioassay. Biometrika 3 60 (1973) 535-542
24. United States Food and Drug Administration. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Appendix 3. ICH guidance for industry Q5A; 1998.
25. Norusis M.J. SPSS 14.0, advanced statistical procedures companion (2005), Prentice Hall Inc., Upper Saddle River
26. International Conference on Harmonisation. Validation of analytical procedures: text and methodology Q2(R1); 2005.
27. Schofield T. Statistical bases for defining level of assurance. Dev Biol (Basel) 123 (2006) 209-216 [discussion 217-222]
28. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 81 (1993) 103-107
29. Notice to readers: manufacturer's recall of human rabies vaccine. MMWR 53 (2004) 1-2
30. United States Food and Drug Administration. Guidance for Industry. Content and format of chemistry, manufacturing and controls information and establishment description information for a vaccine or related product; 1999.
31. Autorino G.L., Battisti A., Deubel V., Ferrari G., Forletta R., Giovannini A., et al. West Nile virus epidemic in horses, Tuscany region, Italy. Emerg Infect Dis 8 12 (2002) 1372-1378
32. Armstrong M.E., Giesa P.A., Davide J.P., Redner F., Waterbury J.A., Rhoad A.E., et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 18 Suppl. 2 (1993) S20-S26
33. Minor P. Gaps in scientific knowledge for the post eradication world. Biologicals 34 2 (2006) 167-170
34. Beasley D.W., Li L., Suderman M.T., and Barrett A.D. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 296 1 (2002) 17-23
35. Bruckner L., Cussler K., Halder M., Barrat J., Castle P., Duchow K., et al. Three Rs approaches in the quality control of inactivated rabies vaccines. Proceedings of the report and recommendations of ECVAM workshop 48. Altern Lab Anim 31 4 (2003) 429-454
36. Chu J.J., Rajamanonmani R., Li J., Bhuvanakantham R., Lescar J., and Ng M.L. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 86 Pt 2 (2005) 405-412